China emerged as Africa’s largest investing economy among the continent’s biggest new foreign-backed developments, anchoring its position through $4.7 billion in major energy and industrial projects, according to annual data released by the United Nations Conference on Trade and Development (UNCTAD).
China Secures Top Investor Spot With Multi-Billion Oil and Metals Projects
Chinese capital concentrated heavily in large-scale resource extraction and infrastructure developments across the continent. According to the UNCTAD annual report, China’s dominance among top-tier projects was driven by three major investments. Golden Concord Holdings, a Hong Kong-based industrial group, initiated a $2.5 billion oil and gas project in Ethiopia, representing the largest Chinese-backed development of the period. This was followed by Fujian Xiang Xin Group’s $1.1 billion oil and gas project in Zambia and CMOC Group’s $1.1 billion metals investment in the Democratic Republic of the Congo (DRC), as outlined in the report.
Global Powers Compete for Critical Minerals and Energy Infrastructure
The CMOC investment in the DRC strengthens China’s presence in a vital source of copper and cobalt, which are essential for electric vehicles, battery manufacturing, and advanced technologies.
Did you know? Despite a nearly one-third decline in the total value of announced greenfield investments across Africa in 2025, the total number of projects actually increased as investors pivoted from mega-projects toward a broader mix of new developments, according to UNCTAD data.
Gulf States and European Investors Maintain Strong Footprint
Frequently Asked Questions
Which country was the largest investor in Africa’s top new projects?
China was the largest investing economy represented among Africa’s biggest new foreign-backed developments, anchored by $4.7 billion across three major projects in Ethiopia, Zambia, and the Democratic Republic of the Congo, according to UNCTAD.
What sectors attracted the highest level of investment?
What was the single largest announced project in Africa?
Explore our latest Africa economic trends analysis or check out global supply chain updates to stay informed on resource market shifts.
- Norwegian Telecom Giant Linked to Myanmar Crimes Against Humanity
- Kimberly Greenwood Nominated by Trump as U.S. Ambassador to Barbados
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)